Korro Bio (NASDAQ:KRRO) Major Shareholder Buys $2,300,881.00 in Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Enterprise Associates 17 New purchased 207,100 shares of Korro Bio stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the acquisition, the insider owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Stock Performance

Korro Bio stock opened at $12.80 on Friday. Korro Bio, Inc. has a one year low of $5.20 and a one year high of $55.89. The company has a 50-day simple moving average of $10.99 and a 200-day simple moving average of $20.18. The firm has a market capitalization of $120.58 million, a P/E ratio of -1.03 and a beta of 2.98.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter, missing the consensus estimate of ($1.93) by ($3.39). The firm had revenue of $1.29 million during the quarter, compared to the consensus estimate of $0.43 million. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 99.63%. As a group, sell-side analysts forecast that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

Wall Street Analyst Weigh In

KRRO has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, January 9th. Wall Street Zen cut Korro Bio from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Clear Str raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 18th. Raymond James Financial upgraded Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price target for the company in a research report on Friday. Finally, Chardan Capital raised Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Key Stories Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Institutional Investors Weigh In On Korro Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in Korro Bio in the third quarter worth approximately $39,000. Wells Fargo & Company MN boosted its stake in Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after buying an additional 2,352 shares in the last quarter. Guggenheim Capital LLC acquired a new stake in Korro Bio in the 4th quarter valued at about $84,000. Jain Global LLC bought a new position in shares of Korro Bio during the 4th quarter valued at about $85,000. Finally, Deutsche Bank AG boosted its position in shares of Korro Bio by 241.9% during the 4th quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after purchasing an additional 9,027 shares in the last quarter. Institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.